Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Sep 09, 2021 9:59am
198 Views
Post# 33830632

Don't expect much reaction to the KOL event

Don't expect much reaction to the KOL event We are nearly a half hour into trading and 242 shares of THTX have traded in four odd lot transactions - that is it! I am not sure how this is even possible. Based on the very low trading volume being seen in THTX, it is apparent there is little anticipation of this event. As such, I have to assume the company has thus far been unable to create any excitement about its NASH KOL, despite the assistance of LSA and Cantor. You may recall when they announced the move to general NASH, they had Loomba on the call and the call was scripted expertly, yet it fell flat because they had built no anticipation for the call and, indeed, surprised everyone with it. So, no one was listening and a great effort went to waste. Worse yet, it ultimately led to the ONO. 

Are we setting up for a repeat of that situation? I sure hope not. Clearly, some effort is being made to promote the KOL this time but it is not clear THTX's NASH prospects have yet to capture any investor's attention.    
<< Previous
Bullboard Posts
Next >>